Overview
There are two types of CAR T-cell therapy, intravenous and oral. Intravenous therapy uses the medicine to administer the cells directly into the bloodstream. Oral therapy is a process that is used during the clinical trials of various types of cancers. This oral therapy is supposed to help boost the immune system of the patient so that the body is better able to fight off the tumors once they begin. Both of these therapies have shown very good results in different clinical trials with various types of malignancies. The global CAR T-cell therapy market focuses on six regions namely North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. The global CAR T-cell therapy market is expected to witness significant growth during the forecast period, owing to ongoing R&D activities in the field of oncology.
Market Drivers
Rising prevalence of cancers is expected to drive growth in the global CAR T-cell therapy market during the forecast period. According to the World Health Organization (WHO), in 2018, around 9.6 million died due to cancer with over 300,000 new cases of cancer being diagnosed each year among children aged 0-19 years across the globe. CAR T-Cell Therapy is witnessing higher adoption in cancer treatment as it does not require aggressive chemotherapy. Hence, such factors are expected to drive growth of the global CAR T-cell therapy market during the forecast period. Furthermore, ongoing R&D activities in the field of oncology are expected to propel the global CAR T-cell therapy market growth over the forecast period.
Market Restraint
Side-effects associated with CAR T-cell therapy, which could lead to cytokine release syndrome are expected to hinder the global CAR T-cell therapy market growth over the forecast period.
Regional Insights
Among regions, North America is expected to witness significant growth in the global CAR T-cell therapy market during the forecast period. This is owing to the presence of strong research and rising clinical trials associated with T-cell therapies in the U.S. Furthermore, Asia Pacific is expected to register a robust growth rate, owing to rising government investment in T-cell therapy R&D.
Competitive Section
Major companies involved in the global CAR T-cell therapy market are Pfizer, Novartis, Kite Pharma, Cellectis, and Juno Therapeutics.
For instance, in April 2021, Bristol Myers Squibb received the U.S. Food and Drug Administration (FDA) approval for idecabtagene vicleucel (Abecma) indicated for multiple myeloma.
Market Taxonomy
This report segments the CAR T-cell therapy market on the basis of antigen type, and therapeutic applications. On the basis of antigen, CAR T-cell therapy market is segmented as CD 19, CD 20, GD2, CD22, CD30, CD33, HER1, HER2, Meso, EGFRvlll, and others.
On the basis of therapeutic applications, CAR T-cell therapy market is segmented into acute lymphocytic leukemia, chronic lymphocytic leukemia, non-hodgkin leukemia, multiple myeloma, pancreatic cancer, neuroblasta, breast cancer, acute myeloid leukemia, hepatocellular carcinoma, colorectal cancer, and other therapeutic applications.
Key features of the study:
• This report provides an in-depth analysis of the CAR T-cell therapy market and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR) (%) for the forecast period (2017 - 2028)
• It elucidates potential revenue opportunities across different segments and explains an attractive investment proposition matrix for this market
• This study also provides valuable insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players
• The report takes into account critical limiting factors such as accuracy issues and the need for calibrating the device several times a day while analyzing the market value and growth (%) during the forecast period
o It includes insights on population dynamics, the number of dental clinic centers, and demand for CAR T-cell Therapy across the globe.
• It profiles leading players in the global CAR T-cell Therapy market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies and future plans
• Key companies covered as a part of this study include Juno Therapeutics, Kite Pharma Inc., Novartis International AG, Bellicum Pharmaceuticals Inc., Celgene Corporation, and Cellectis.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions with respect to their future product launch, technology upgrade, market expansion, and marketing tactics
• The global CAR T-cell Therapy market report caters to various stakeholders in this industry, including investors, raw material manufacturer, contract manufacturer, device manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would greatly benefit in decision making through the various strategy matrices used in analyzing the CAR T-cell Therapy market.
Detailed Segmentation:
• Global CAR T-cell Therapy Market, By Targeted Antigen:
o CD 19
o CD 20
o GD2
o CD22
o CD30
o CD33
o HER1
o HER2
o Meso
o EGFRvlll
o Others
• Global CAR T-cell Therapy Market, By Therapeutic Application:
o Acute Lymphocytic Leukemia
o Chronic Lymphocytic Leukemia
o Non Hodgkin Leukemia
o Multiple Myeloma
o Pancreatic Cancer
o Neuroblasta
o Breast Cancer
o Acute Myeloid Leukemia
o Hepatocellular Carcinoma
o Colorectal Cancer
o Others
• Global CAR T-cell Therapy Market, By Geography:
o North America
• North America CAR T-cell Therapy Market, By Targeted Antigen:
o CD 19
o CD 20
o GD2
o CD22
o CD30
o CD33
o HER1
o HER2
o Meso
o EGFRvlll
o Others
• North America CAR T-cell Therapy Market, By Technique:
o Acute Lymphocytic Leukemia
o Chronic Lymphocytic Leukemia
o Non Hodgkin Leukemia
o Multiple Myeloma
o Pancreatic Cancer
o Neuroblasta
o Breast Cancer
o Acute Myeloid Leukemia
o Hepatocellular Carcinoma
o Colorectal Cancer
o Others
o Europe
• Europe CAR T-cell Therapy Market, By Targeted Antigen:
o CD 19
o CD 20
o GD2
o CD22
o CD30
o CD33
o HER1
o HER2
o Meso
o EGFRvlll
o Others
• Europe CAR T-cell Therapy Market, By Technique:
o Acute Lymphocytic Leukemia
o Chronic Lymphocytic Leukemia
o Non Hodgkin Leukemia
o Multiple Myeloma
o Pancreatic Cancer
o Neuroblasta
o Breast Cancer
o Acute Myeloid Leukemia
o Hepatocellular Carcinoma
o Colorectal Cancer
o Others
o Asia Pacific
• Asia Pacific CAR T-cell Therapy Market, By Targeted Antigen:
o CD 19
o CD 20
o GD2
o CD22
o CD30
o CD33
o HER1
o HER2
o Meso
o EGFRvlll
o Others
• Asia Pacific CAR T-cell Therapy Market, By Technique:
o Acute Lymphocytic Leukemia
o Chronic Lymphocytic Leukemia
o Non Hodgkin Leukemia
o Multiple Myeloma
o Pancreatic Cancer
o Neuroblasta
o Breast Cancer
o Acute Myeloid Leukemia
o Hepatocellular Carcinoma
o Colorectal Cancer
o Others
• Latin America
• Latin America CAR T-cell Therapy Market, By Targeted Antigen:
o CD 19
o CD 20
o GD2
o CD22
o CD30
o CD33
o HER1
o HER2
o Meso
o EGFRvlll
o Others
• Latin America CAR T-cell Therapy Market, By Technique:
o Acute Lymphocytic Leukemia
o Chronic Lymphocytic Leukemia
o Non Hodgkin Leukemia
o Multiple Myeloma
o Pancreatic Cancer
o Neuroblasta
o Breast Cancer
o Acute Myeloid Leukemia
o Hepatocellular Carcinoma
o Colorectal Cancer
o Others
o Middle East
• Middle East CAR T-cell Therapy Market, By Targeted Antigen:
o CD 19
o CD 20
o GD2
o CD22
o CD30
o CD33
o HER1
o HER2
o Meso
o EGFRvlll
o Others
• Middle East CAR T-cell Therapy Market, By Technique:
o Acute Lymphocytic Leukemia
o Chronic Lymphocytic Leukemia
o Non Hodgkin Leukemia
o Multiple Myeloma
o Pancreatic Cancer
o Neuroblasta
o Breast Cancer
o Acute Myeloid Leukemia
o Hepatocellular Carcinoma
o Colorectal Cancer
o Others
o Africa
• Africa CAR T-cell Therapy Market, By Targeted Antigen:
o CD 19
o CD 20
o GD2
o CD22
o CD30
o CD33
o HER1
o HER2
o Meso
o EGFRvlll
o Others
• Africa CAR T-cell Therapy Market, By Technique:
o Acute Lymphocytic Leukemia
o Chronic Lymphocytic Leukemia
o Non Hodgkin Leukemia
o Multiple Myeloma
o Pancreatic Cancer
o Neuroblasta
o Breast Cancer
o Acute Myeloid Leukemia
o Hepatocellular Carcinoma
o Colorectal Cancer
o Others
• Company Profiles
o Novartis International AG *
o Company Overview
o Product Portfolio
o Financial Performance
o Key Strategies
o Recent Developments
o Future Plans
o Kite Pharma Inc.
o Juno Therapeutics
o Bellicum Pharmaceuticals, Inc.
o Celgene Corporation
o Cellectis
"*" marked represents similar segmentation in other categories in the respective section.
•
Table of Contents
1. Research Objective and assumption
o Research Objectives
o Assumptions
o Abbreviations
2. Market Purview
o Report Description
o Market Definition and Scope
o Executive Summary
o Market Snippet By Targeted Antigen
o Market Snippet By Therapeutic Application
o Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
o Market Dynamics
o Drivers
o Restraints
o Market Opportunities
o Regulatory Scenario
o Industry Trend
o Epidemiology/Prevalence/Incidence
o Merger and Acquisitions
o New Product Approvals/Launch
4. Global CAR T-cell Therapy Market, By Targeted Antigen, 2017 - 2028 (US$ Million)
o Introduction
o Market Share Analysis, 2017 and 2028 (%)
o Y-O-Y Growth Analysis, 2017 - 2028
o Segment Trends
o CD 19
o Introduction
o Market Size and Forecast, and Y-O-Y Growth, 2017 - 2028, (US$ Million)
o CD 20
o Introduction
o Market Size and Forecast, and Y-O-Y Growth, 2017 - 2028, (US$ Million)
o GD2
o Introduction
o Market Size and Forecast, and Y-O-Y Growth, 2017 - 2028, (US$ Million)
o CD22
o Introduction
o Market Size and Forecast, and Y-O-Y Growth, 2017 - 2028, (US$ Million)
o CD30
o Introduction
o Market Size and Forecast, and Y-O-Y Growth, 2017 - 2028, (US$ Million)
o CD33
o Introduction
o Market Size and Forecast, and Y-O-Y Growth, 2017 - 2028, (US$ Million)
o HER1
o Introduction
o Market Size and Forecast, and Y-O-Y Growth, 2017 - 2028, (US$ Million)
o HER2
o Introduction
o Market Size and Forecast, and Y-O-Y Growth, 2017 - 2028, (US$ Million)
o Meso
o Introduction
o Market Size and Forecast, and Y-O-Y Growth, 2017 - 2028, (US$ Million)
o EGFRvlll
o Introduction
o Market Size and Forecast, and Y-O-Y Growth, 2017 - 2028, (US$ Million)
o Others
o Introduction
o Market Size and Forecast, and Y-O-Y Growth, 2017 - 2028, (US$ Million)
5. Global CAR T-cell Therapy Market, By Therapeutic Application, 2017 - 2028 (USD Million)
o Introduction
o Market Share Analysis, 2017 and 2028 (%)
o Y-O-Y Growth Analysis, 2017 - 2028
o Segment Trends
o Acute Lymphocytic Leukemia
o Introduction
o Market Share Analysis, 2017 and 2028 (%)
o Y-O-Y Growth Analysis, 2017 - 2028
o Chronic Lymphocytic Leukemia
o Introduction
o Market Size and Forecast, and Y-O-Y Growth, 2017 - 2028, (US$ Million)
o Non Hodgkin Leukemia
o Introduction
o Market Size and Forecast, and Y-O-Y Growth, 2017 - 2028, (US$ Million)
o Multiple Myeloma
o Introduction
o Market Size and Forecast, and Y-O-Y Growth, 2017 - 2028, (US$ Million)
o Pancreatic Cancer
o Introduction
o Market Size and Forecast, and Y-O-Y Growth, 2017 - 2028, (US$ Million)
o Neuroblasta
o Introduction
o Market Size and Forecast, and Y-O-Y Growth, 2017 - 2028, (US$ Million)
o Breast Cancer
o Introduction
o Market Size and Forecast, and Y-O-Y Growth, 2017 - 2028, (US$ Million)
o Acute Myeloid Leukemia
o Introduction
o Market Size and Forecast, and Y-O-Y Growth, 2017 - 2028, (US$ Million)
o Hepatocellular Carcinoma
o Introduction
o Market Size and Forecast, and Y-O-Y Growth, 2017 - 2028, (US$ Million)
o Colorectal Cancer
o Introduction
o Market Size and Forecast, and Y-O-Y Growth, 2017 - 2028, (US$ Million)
o Others
o Introduction
o Market Size and Forecast, and Y-O-Y Growth, 2017 - 2028, (US$ Million)
6. Global CAR T-cell Therapy Market, By Regions, 2017 - 2028 (US$ Million)
o Introduction
o Market Share Analysis, By Region, 2017 and 2028 (%)
o Y-O-Y Growth Analysis, For Regions, 2017 - 2028
o North America
o Market Share Analysis, By Segments, 2017 and 2028 (%)
o Y-O-Y Growth Analysis, By Segments, 2017 - 2028
o Market Size and Forecast, By Targeted Antigen, 2017 - 2028 (US$ Million)
o Market Size and Forecast, By Therapeutic Application, 2017 - 2028 (US$ Million)
o Europe
o Market Share Analysis, By Segments, 2017 and 2028 (%)
o Y-O-Y Growth Analysis, By Segments, 2017 - 2028
o Market Size and Forecast, By Targeted Antigen, 2017 - 2028 (US$ Million)
o Market Size and Forecast, By Therapeutic Application, 2017 - 2028 (US$ Million)
o Asia Pacific
o Market Share Analysis, By Segments, 2017 and 2028 (%)
o Y-O-Y Growth Analysis, By Segments, 2017 - 2028
o Market Size and Forecast, By Targeted Antigen, 2017 - 2028 (US$ Million)
o Market Size and Forecast, By Therapeutic Application, 2017 - 2028 (US$ Million)
o Latin America
o Market Share Analysis, By Segments, 2017 and 2028 (%)
o Y-O-Y Growth Analysis, By Segments, 2017 - 2028
o Market Size and Forecast, By Targeted Antigen, 2017 - 2028 (US$ Million)
o Market Size and Forecast, By Therapeutic Application, 2017 - 2028 (US$ Million)
o Africa
o Market Share Analysis, By Segments, 2017 and 2028 (%)
o Y-O-Y Growth Analysis, By Segments, 2017 - 2028
o Market Size and Forecast, By Targeted Antigen, 2017 - 2028 (US$ Million)
o Market Size and Forecast, By Therapeutic Application, 2017 - 2028 (US$ Million)
o Middle East
o Market Share Analysis, By Segments, 2017 and 2028 (%)
o Y-O-Y Growth Analysis, By Segments, 2017 - 2028
o Market Size and Forecast, By Targeted Antigen, 2017 - 2028 (US$ Million)
o Market Size and Forecast, By Therapeutic Application, 2017 - 2028 (US$ Million)
7. Competitive Landscape
o Heat Map Analysis
o Market Share Analysis
o Company Profiles
o Novartis International AG
o Company Overview
o Product Portfolio
o Financial Performance
o Recent Developments/Updates
o Future Plans
o Kite Pharma Inc.
o Company Overview
o Product Portfolio
o Financial Performance
o Recent Developments/Updates
o Future Plans
o Juno Therapeutics
o Company Overview
o Product Portfolio
o Financial Performance
o Recent Developments/Updates
o Future Plans
o Bellicum Pharmaceuticals, Inc.
o Company Overview
o Product Portfolio
o Financial Performance
o Recent Developments/Updates
o Future Plans
o Celgene Corporation
o Company Overview
o Product Portfolio
o Financial Performance
o Recent Developments/Updates
o Future Plans
o Cellectis
o Company Overview
o Product Portfolio
o Financial Performance
o Recent Developments/Updates
o Future Plans
o Analyst Views
8. Section
o References
o Research Methodology
o About us and Sales Contact
*Browse 90 market data tables and 40 figures on "CAR T-cell Therapy Market - Global forecast to 2024".
Request Discount 
Inquire Before Buy
